Dr. John Cush RheumNow
10 months 3 weeks ago
Off the Shelf: CAR-T
Dr. Akhil Sood reports on abstract 0663 (iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy) presented at#ACR25.
https://t.co/mj4b5cCInC https://t.co/s34atFCMlx
Dr. John Cush RheumNow
10 months 3 weeks ago
AI in Fellow Recruitment: A New Dawn in Medical Education?
Drs. Mrinalini Dey and Bharat Kumar abstract 2174 (Using Natural Language Processing to Identify Character Strengths in Rheumatology Fellowship Candidate Applications: A Feasibility Study) presented at #ACR25. https://t.co/gGx4zZlfAm
Dr. John Cush RheumNow
10 months 3 weeks ago
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA
At #ACR25, abstract 1039, "Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis," highlights the critical economic and ethical dimensions of CAR-T cell therapy in autoimmune https://t.co/Rci0dL7THj
Dr. John Cush RheumNow
10 months 3 weeks ago
“It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change." – Charles Darwin
Dr. John Cush RheumNow
10 months 3 weeks ago
Are we putting the CAR-T before the horse?
CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure. https://t.co/gF9FXjAZ7F
Dr. John Cush RheumNow
10 months 3 weeks ago
B Cell Depletion: Check the Lymph Node
Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25.
https://t.co/bvZMGWNzfe https://t.co/dB6iQlgoYx
Dr. John Cush RheumNow
10 months 3 weeks ago
900,000 vs 9
It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed.
It takes less than nine minutes to make your patient feel seen, understood and reassured.
If you skip the 9 minutes, you wasted the https://t.co/o7BaWjS4HB
Dr. John Cush RheumNow
10 months 3 weeks ago
IL-23 Blockade Goes Oral
A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and https://t.co/7awBk16ZrQ
Dr. John Cush RheumNow
10 months 3 weeks ago
Stopping therapy in GCA
At #ACR25 we saw the SELECT-GCA extension data presented in the first plenary session, looking at the second year after the 52 week original study, comparing upadacitinib versus placebo in GCA. In this second year, patients in remission on upadacitinib https://t.co/GaYNWr3Sjq
I've done thousands of interviews; mostly for medical school admissions or medical and research employment. They’re all the same. I'm looking for the “right one” and the interviewee is somewhere between apprehension, uncertainty and hope. From all this experience I’ve developed my own perspective on interviews and interviewing that has been amended in the digital/virtual era.
